Clinical trials: Major Neurocognitive Disorder
Alzheimer's Disease
Memantine and Antipsychotics Use
To investigate the potential to reduce concomitant antipsychotic medication use in subjects with moderate dementia of Alzheimer's type, treated with memantine.
- Trial name
- MemAP (NCT00649220)
- Testing
- Memantine
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Merz Pharmaceuticals GmbH
Alzheimer's Disease
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
This is a prospective, multicenter, open-label study. Following screening and baseline assessments, eligible patients will be switched to rivastigmine and will enter the 16 week run-in rivastigmine treatment phase.
- Trial name
- NCT00234637
- Testing
- Rivastigmine, memantine
- Where
- France
- Volunteers
- 204 people
- Sponsor
- Novartis
Chronic Insomnia
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance
- Trial name
- NCT00325728
- Testing
- Ramelteon
- Where
- 72 sites in United States
- Volunteers
- 74 people
- Sponsor
- Takeda
Alzheimer's Disease
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
The primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT00857233
- Testing
- Memantine
- Where
- 33 sites in Canada
- Volunteers
- 297 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease
A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes
The purpose of the study is to evaluate the efficacy and safety of Aricept in nursing home patients with severe Alzheimer's disease.
- Trial name
- NCT00630851
- Testing
- Donepezil (Aricept)
- Where
- 53 sites in Sweden
- Volunteers
- 249 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per…
- Trial name
- NCT02989402
- Testing
- Rivastigmine
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction
Trifecta Research Study
This observational study evaluates the impact of Ibogaine-Magnesium (IM), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), Magnetic e-Resonance Therapy (MeRT), and Physiological Supplementation (PS) on posttraumatic stress disorder…
- Conditions
- PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder
- Trial name
- NCT07717866
- Testing
- Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Axial Therapeutic Research
Alzheimer's Disease
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.
- Trial name
- NCT01766336
- Testing
- Group 1 ELND005, Group 2 ELND005
- Where
- 46 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- OPKO Health, Inc.
Major Depressive Disorder
Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression
The Purposes of this Study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression.
- Trial name
- NCT00042575
- Testing
- Duloxetine
- Where
- 9 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Covid19, Corona Virus Infection
Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831
The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.
- Conditions
- Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection
- Trial name
- NEUROSIVIR (NCT04480333)
- Testing
- Drug: NA-831 - 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Biomed Industries, Inc.
Alzheimer's Disease
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.
- Trial name
- NCT00478205
- Testing
- Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
- Where
- United States
- Volunteers
- 1,467 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease, Dementia
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT00096473
- Testing
- Donepezil hydrochloride
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 229 people
- Sponsor
- Eisai Inc.
Major Depressive Disorder
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
- Trial name
- NCT06419608
- Testing
- BHV-7000
- Where
- 62 sites in United States
- Volunteers
- 336 people
- Sponsor
- Biohaven Therapeutics Ltd.
Dementia of the Alzheimer's Type
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
The objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent…
- Trial name
- NCT00322153
- Testing
- memantine ER
- Where
- 83 sites in United States, Argentina and 2 more
- Volunteers
- 677 people
- Sponsor
- Forest Laboratories
Alzheimer Disease
Bryostatin Treatment of Moderately Severe Alzheimer's Disease
To evaluate the safety, tolerability, and long-term efficacy of bryostatin 1 (hereafter referred to as bryostatin) for the treatment of moderately severe Alzheimer's disease (AD).
- Trial name
- NCT04538066
- Testing
- Bryostatin 1
- Where
- 19 sites in United States
- Volunteers
- 122 people
- Sponsor
- Neurotrope Bioscience, Inc.
Alzheimer's Disease
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating safety and efficacy of donepezil hydrochloride in patients with moderate to severe Alzheimer's disease.
- Trial name
- SAVE (NCT02097056)
- Testing
- Donepezil HCL
- Where
- 13 sites in South Korea
- Volunteers
- 171 people
- Sponsor
- Eisai Korea Inc.
Alzheimer Disease
Neuro RX Gamma - Pivotal Phase
The active Neuro RX Gamma device uses non-invasive near-infrared energy delivered to the brain with the intention to improve cognitive functioning and quality of life in patients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT03484143
- Testing
- Active Neuro RX Gamma device
- Where
- 9 sites in United States, Canada
- Volunteers
- 228 people
- Sponsor
- Vielight Inc.
Severe Alzheimer Disease
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
- Trial name
- NCT03765762
- Testing
- GRF6019
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alkahest, Inc.
Dementia, Alzheimer Disease
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.
- Trial name
- NCT00216593
- Testing
- galantamine hydrobromide
- Volunteers
- 415 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Major Depressive Disorder, Dementia
Vortioxetine in Patients With Depression and Early Dementia
This study evaluates the effectiveness of vortioxetine on depressive symptoms in patients with depression and early dementia
- Trial name
- MEMORY (NCT04294654)
- Testing
- Vortioxetine
- Where
- 24 sites in Estonia, France and 4 more
- Volunteers
- 82 people
- Sponsor
- H. Lundbeck A/S